Systematic review / meta-analysis / 2012
Soy isoflavone supplementation reduced blood pressure in hypertensive subjects, but showed no significant effect in normotensive individuals.
A meta-analysis of 11 randomized controlled trials evaluated the effect of dietary soy isoflavones on blood pressure. Overall, soy isoflavones resulted in a mean decrease of 2.5 mm Hg (95% CI: -5.35 to 0.34, P = 0.08) for systolic blood pressure (SBP) and 1.5 mm Hg (95% CI: -3.09 to 0.17, P = 0.08) for diastolic blood pressure (DBP) compared to placebo. In subgroup analyses of hypertensive subjects (5 trials), soy isoflavones significantly reduced SBP by -5.94 mm Hg (95% CI: -10.55 to -1.34, P = 0.01) and DBP by -3.35 mm Hg (95% CI: -6.52 to -0.19, P = 0.04). No significant reduction was found in normotensive subjects (6 trials; SBP: 0.29 mm Hg, P = 0.83; DBP: -0.43 mm Hg, P = 0.50). Authors noted larger trials are needed to confirm the findings.
- Study type
- Meta-analysis of randomized controlled trials
- Who was studied
- Participants across 11 randomized controlled trials (including 5 trials of hypertensive subjects and 6 of normotensive subjects)
- What was measured
- Systolic and diastolic blood pressure
THE PAPER
Effect of soy isoflavones on blood pressure: a meta-analysis of randomized controlled trials.
Liu XX, Li SH, Chen JZ, Sun K, Wang XJ, Wang XG, Hui RT. Nutr Metab Cardiovasc Dis, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.